Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA; Department of Surgery, University of Rochester Cancer Center National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base, Rochester, NY, USA.
Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Lancet. 2021 Nov 20;398(10314):1894-1904. doi: 10.1016/S0140-6736(21)01789-X. Epub 2021 Nov 3.
Older adults with advanced cancer are at a high risk for treatment toxic effects. Geriatric assessment evaluates ageing-related domains and guides management. We examined whether a geriatric assessment intervention can reduce serious toxic effects in older patients with advanced cancer who are receiving high risk treatment (eg, chemotherapy).
In this cluster-randomised trial, we enrolled patients aged 70 years and older with incurable solid tumours or lymphoma and at least one impaired geriatric assessment domain who were starting a new treatment regimen. 40 community oncology practice clusters across the USA were randomly assigned (1:1) to the intervention (oncologists received a tailored geriatric assessment summary and management recommendations) or usual care (no geriatric assessment summary or management recommendations were provided to oncologists) by means of a computer-generated randomisation table. The primary outcome was the proportion of patients who had any grade 3-5 toxic effect (based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4) over 3 months. Practice staff prospectively captured toxic effects. Masked oncology clinicians reviewed medical records to verify. The study was registered with ClinicalTrials.gov, NCT02054741.
Between July 29, 2014, and March 13, 2019, we enrolled 718 patients. Patients had a mean age of 77·2 years (SD 5·4) and 311 (43%) of 718 participants were female. The mean number of geriatric assessment domain impairments was 4·5 (SD 1·6) and was not significantly different between the study groups. More patients in intervention group compared with the usual care group were Black versus other races (40 [11%] of 349 patients vs 12 [3%] of 369 patients; p<0·0001) and had previous chemotherapy (104 [30%] of 349 patients vs 81 [22%] of 369 patients; p=0·016). A lower proportion of patients in the intervention group had grade 3-5 toxic effects (177 [51%] of 349 patients) compared with the usual care group (263 [71%] of 369 patients; relative risk [RR] 0·74 (95% CI 0·64-0·86; p=0·0001). Patients in the intervention group had fewer falls over 3 months (35 [12%] of 298 patients vs 68 [21%] of 329 patients; adjusted RR 0·58, 95% CI 0·40-0·84; p=0·0035) and had more medications discontinued (mean adjusted difference 0·14, 95% CI 0·03-0·25; p=0·015).
A geriatric assessment intervention for older patients with advanced cancer reduced serious toxic effects from cancer treatment. Geriatric assessment with management should be integrated into the clinical care of older patients with advanced cancer and ageing-related conditions.
National Cancer Institute.
患有晚期癌症的老年人存在治疗毒性作用的高风险。老年评估评估与衰老相关的领域并指导管理。我们研究了老年评估干预是否可以减少接受高风险治疗(例如化疗)的晚期癌症老年患者的严重毒性作用。
在这项聚类随机试验中,我们招募了年龄在 70 岁及以上、患有不可治愈的实体瘤或淋巴瘤且至少有一个受损老年评估领域的患者,他们正在开始新的治疗方案。美国 40 个社区肿瘤学实践集群通过计算机生成的随机分配表被随机分配(1:1)至干预组(肿瘤学家收到量身定制的老年评估摘要和管理建议)或常规护理组(肿瘤学家未收到老年评估摘要或管理建议)。主要结局是在 3 个月内任何 3-5 级毒性作用(基于国家癌症研究所不良事件通用术语标准第 4 版)的患者比例。实践人员前瞻性地记录毒性作用。经过掩蔽的肿瘤学临床医生审查医疗记录进行验证。该研究在 ClinicalTrials.gov 上注册,NCT02054741。
在 2014 年 7 月 29 日至 2019 年 3 月 13 日之间,我们招募了 718 名患者。患者的平均年龄为 77.2 岁(标准差 5.4),718 名参与者中有 311 名(43%)为女性。平均有 4.5 个(标准差 1.6)老年评估领域受损,两组之间没有显著差异。与常规护理组相比,干预组中更多的患者为黑人而非其他种族(349 名患者中的 40[11%]与 369 名患者中的 12[3%];p<0.0001),且有既往化疗史(349 名患者中的 104[30%]与 369 名患者中的 81[22%];p=0.016)。干预组中发生 3-5 级毒性作用的患者比例较低(349 名患者中的 177[51%]与 369 名患者中的 263[71%];相对风险 [RR] 0.74(95% CI 0.64-0.86;p=0.0001)。干预组患者在 3 个月内的跌倒次数较少(298 名患者中的 35[12%]与 329 名患者中的 68[21%];调整后的 RR 0.58,95% CI 0.40-0.84;p=0.0035),且更多药物被停用(平均调整后的差异为 0.14,95% CI 0.03-0.25;p=0.015)。
针对晚期癌症老年患者的老年评估干预措施减少了癌症治疗的严重毒性作用。老年评估和管理应纳入晚期癌症和与衰老相关疾病老年患者的临床护理中。
美国国立癌症研究所。